CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Jun

Today In Oncology

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

Related Videos

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Can AI Provide an Early Alert for Breast Cancer Before Diagnosis

Urologic Surgeon Sworn in as AMA President

Head and Neck Cancer HPV-DeepSeek May Identify Earlier Signs of Postoperative Recurrence

FDA Approves Atezolizumab for Adjuvant Treatment of MRD-Positive MIBC

Perioperative Serplulimab in PD-L1–Positive Gastric Cancer